SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Individuals interested in viewing the live presentation can register for the free event here: Noble Healthcare Conference Registration. A video replay of the presentation will be available for 90 days following the event on the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com and on Channelchek: www.channelchek.com.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.
Contact
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.90 |
| Daily Change: | 0.05 6.23 |
| Daily Volume: | 1,012,313 |
| Market Cap: | US$116.250M |
May 13, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
